CORCEPT THERAPEUTICS INC (CORT) Spending and interest coverage
- R&D / revenue · 12 months: Value 30.56%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 11.57%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 30.56% | Research and development expense / revenue. Period ending 2026-06-30. $253.86M ÷ $830.81M × 100 ≈ 30.56% |
| Stock-based compensation / revenue · 12 months | 11.57% | Share-based compensation / revenue. Period ending 2026-06-30. $96.11M ÷ $830.81M × 100 ≈ 11.57% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 253.86M USD | Research and Development Expense |
| Revenue | 830.81M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 96.11M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 6.41M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $253.86M | $830.81M | $96.11M | $6.41M | (m) | 30.56% | 11.57% | (m) | (m) |
| 2026-03-31 | $260.44M | $769.10M | $85.71M | $-8.22M | (m) | 33.86% | 11.14% | (m) | (m) |
| 2025-12-31 | $254.91M | $761.41M | $84.50M | $44.80M | (m) | 33.48% | 11.10% | (m) | (m) |
| 2025-09-30 | $260.35M | $741.17M | $80.53M | $65.57M | (m) | 35.13% | 10.86% | (m) | (m) |
| 2025-06-30 | $250.84M | $716.08M | $73.75M | $101.95M | (m) | 35.03% | 10.30% | (m) | (m) |
| 2025-03-31 | $249.12M | $685.45M | $69.94M | $110.87M | (m) | 36.34% | 10.20% | (m) | (m) |
| 2024-12-31 | $246.89M | $675.04M | $61.35M | $136.95M | (m) | 36.57% | 9.09% | (m) | (m) |
| 2024-09-30 | $231.29M | $628.55M | $57.62M | $143.36M | (m) | 36.80% | 9.17% | (m) | (m) |
| 2024-06-30 | $217.48M | $569.61M | $54.40M | $127.94M | (m) | 38.18% | 9.55% | (m) | (m) |
| 2024-03-31 | $202.01M | $523.53M | $51.05M | $121.93M | (m) | 38.59% | 9.75% | (m) | (m) |
| 2023-12-31 | $184.35M | $482.38M | $48.94M | $107.28M | (m) | 38.22% | 10.15% | (m) | (m) |
| 2023-09-30 | $166.40M | $450.03M | $46.40M | $98.11M | (m) | 36.98% | 10.31% | (m) | (m) |
| 2023-06-30 | $154.17M | $428.15M | $44.07M | $98.87M | (m) | 36.01% | 10.29% | (m) | (m) |
| 2023-03-31 | $143.72M | $413.82M | $42.82M | $100.72M | (m) | 34.73% | 10.35% | (m) | (m) |
| 2022-12-31 | $130.99M | $401.86M | $42.44M | $112.63M | (m) | 32.60% | 10.56% | (m) | (m) |
| 2022-09-30 | $122.76M | $397.62M | $42.73M | $126.80M | (m) | 30.87% | 10.75% | (m) | (m) |
| 2022-06-30 | $117.56M | $392.03M | $43.13M | $131.10M | (m) | 29.99% | 11.00% | (m) | (m) |
| 2022-03-31 | $112.96M | $380.23M | $43.59M | $131.61M | (m) | 29.71% | 11.46% | (m) | (m) |
| 2021-12-31 | $113.86M | $365.98M | $42.93M | $124.48M | (m) | 31.11% | 11.73% | (m) | (m) |
| 2021-09-30 | $113.62M | $352.89M | $40.55M | $118.32M | (m) | 32.20% | 11.49% | (m) | (m) |
| 2021-06-30 | $119.40M | $343.09M | $38.30M | $106.81M | (m) | 34.80% | 11.16% | (m) | (m) |
| 2021-03-31 | $117.66M | $340.06M | $35.72M | $110.13M | (m) | 34.60% | 10.50% | (m) | (m) |
| 2020-12-31 | $114.76M | $353.87M | $33.54M | $128.20M | (m) | 32.43% | 9.48% | (m) | (m) |
| 2020-09-30 | $110.80M | $356.03M | $32.72M | $132.71M | (m) | 31.12% | 9.19% | (m) | (m) |
| 2020-06-30 | $99.74M | $351.21M | $31.29M | $140.99M | (m) | 28.40% | 8.91% | (m) | (m) |
| 2020-03-31 | $94.90M | $334.90M | $30.54M | $130.36M | (m) | 28.34% | 9.12% | (m) | (m) |
| 2019-12-31 | $89.02M | $306.49M | $29.31M | $111.61M | (m) | 29.04% | 9.56% | (m) | (m) |
| 2019-09-30 | $83.50M | $285.42M | $27.97M | $101.49M | (m) | 29.25% | 9.80% | (m) | (m) |
| 2019-06-30 | $79.55M | $268.36M | $27.21M | $91.46M | (m) | 29.64% | 10.14% | (m) | (m) |
| 2019-03-31 | $78.44M | $258.42M | $25.49M | $87.46M | (m) | 30.35% | 9.86% | (m) | (m) |
| 2018-12-31 | $75.25M | $251.25M | $23.75M | $89.50M | (m) | 29.95% | 9.45% | (m) | (m) |
| 2018-09-30 | $70.08M | (m) | $21.31M | $86.30M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $62.92M | (m) | $18.43M | $76.95M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $50.25M | (m) | $15.61M | $69.11M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $40.38M | (m) | $13.36M | $52.85M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $33.23M | (m) | $11.49M | $36.16M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $28.59M | (m) | $9.69M | $25.61M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $26.39M | (m) | $8.15M | $14.33M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $23.84M | (m) | $7.06M | $10.18M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $21.45M | (m) | $6.59M | $6.82M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $18.01M | (m) | $6.31M | $3.85M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $15.68M | (m) | $6.22M | $1.18M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $15.42M | (m) | $6.01M | $-3.44M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $15.12M | (m) | $5.91M | $-8.17M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $14.55M | (m) | $5.58M | $-13.38M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $15.46M | (m) | $5.23M | $-18.79M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $18.37M | (m) | $5.20M | $-27.62M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $21.15M | (m) | $5.13M | $-34.57M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $23.26M | (m) | $5.22M | $-39.21M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $23.50M | (m) | $5.26M | $-43.41M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $20.47M | (m) | $5.20M | $-41.50M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $18.76M | (m) | $4.93M | $-41.45M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $16.61M | (m) | $4.61M | $-39.38M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $14.79M | (m) | $4.23M | $-36.19M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $14.07M | (m) | $5.31M | $-36.27M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $15.86M | (m) | $5.30M | $-36.22M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $16.08M | (m) | $5.26M | $-34.99M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $19.62M | (m) | $5.24M | $-36.26M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $21.00M | (m) | $3.44M | $-32.33M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $18.95M | (m) | $2.12M | $-27.44M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $14.40M | $29.00K | $1.80M | $-20.25M | (m) | 49662.07% | 6203.45% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |